Astrazeneca Plc ADR (NY: AZN )
54.17 USD UNCHANGED Last Price Updated: 7:43 PM EDT, Sep 24, 2020 Add to My Watchlist
Press releases about Astrazeneca Plc ADR
SAPHNELO (anifrolumab) Approved in the US for Moderate to Severe Systemic Lupus Erythematosus
August 02, 2021
AstraZeneca’s SAPHNELO™ (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard...
HUTCHMED and AstraZeneca Initiate Phase II Trial of ORPATHYS® in Patients with MET Amplified Gastric Cancer
July 27, 2021
— Follows multiple Phase II studies of ORPATHYS® in Asia including VIKTORY, which reported an 50% objective response rate (ORR) in gastric cancer patients whose tumors harbor MET amplification —
BYDUREON BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older
July 23, 2021
AstraZeneca’s BYDUREON BCise (exenatide extended-release), once-weekly injectable suspension has been approved in the US for the treatment of type 2 diabetes (T2D); to improve glycemic control in...
From AB Newswire
HUTCHMED Announces First Commercial Sale of ORPATHYS® in China, Triggering a US$25 million Milestone Payment from AstraZeneca
July 13, 2021
F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
July 08, 2021
Tezepelumab Regulatory Submission Accepted and Granted FDA Priority Review in the US for the Treatment of Patients with Asthma
July 08, 2021
AstraZeneca’s Biologics License Application (BLA) for tezepelumab has been accepted and granted Priority Review for the treatment of asthma from the US Food and Drug Administration (FDA). Tezepelumab...
Phase III pivotal trial of once weekly exenatide in adolescents aged 10–17 shows benefit for the treatment of type 2 diabetes
June 25, 2021
Positive results from the Phase III pivotal trial (NCT01554618) showed AstraZeneca’s exenatide extended-release 2mg once weekly significantly reduced blood sugar—as measured by HbA1c—versus placebo in...
HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations
June 22, 2021
Dyadic International (NASDAQ: DYAI): A Unique Approach to World Vaccination (DYAI, AZN, MRNA, NVAX, PFE, JNJ, BNTX)
June 09, 2021
CALQUENCE Demonstrated Fewer Incidences of Atrial Fibrillation Versus Ibrutinib in Previously Treated Patients With Chronic Lymphocytic Leukemia and Sustained Patient Benefit at Four Years in the Fron
June 07, 2021
Final results from the head-to-head ELEVATE-RR Phase III trial of AstraZeneca’s CALQUENCE (acalabrutinib) demonstrated non-inferior progression-free survival (PFS) and statistically significantly fewer...
IMFINZI Demonstrated Unprecedented Survival in Unresectable Stage III Lung Cancer With 43% Of Patients Surviving Five Years
June 04, 2021
Updated results from the positive PACIFIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated a sustained, clinically meaningful overall survival (OS) and progression-free survival...
LYNPARZA® (olaparib) reduced the risk of cancer recurrence by 42% in the adjuvant treatment of patients with germline BRCA-mutated high-risk early breast cancer in OlympiA Phase III trial
June 03, 2021
AstraZeneca and Merck & Co., Inc., known as MSD outside the US and Canada, today announced results from the OlympiA Phase III trial showed LYNPARZA® (olaparib) demonstrated a statistically significant...
Proteros biostructures GmbH (“Proteros”) today announced that it has signed an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to jointly discover and develop novel small molecules for the potential...
HUTCHMED Highlights Clinical Data to be Presented at the Upcoming ASCO21 Virtual Scientific Program
May 20, 2021
AstraZeneca ASCO 2021 Data Support Ambition to Revolutionize Cancer Outcomes by Treating Earlier and Transforming the Patient Experience
May 19, 2021
AstraZeneca will present new data underscoring its ambition to redefine cancer care at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 4 to 8, 2021.
New FASENRA® Data From the MELTEMI Extension Trial Confirm Long-Term Safety and Efficacy in Severe Eosinophilic Asthma for up to Five Years
May 19, 2021
Results from a new integrated analysis including data from the MELTEMI Phase III open-label extension trial showed FASENRA® (benralizumab) was well-tolerated for up to five years, with a long-term...
New Tezepelumab Data Continue to Strengthen Profile for a Broad Population of Severe Asthma Patients
May 13, 2021
Detailed results from the pivotal NAVIGATOR Phase III trial showed AstraZeneca and Amgen’s tezepelumab, a potential first-in-class treatment, demonstrated superiority across every primary and key...
AVEO Oncology Reports First Quarter 2021 Financial Results and Provides Business Update
May 10, 2021
AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today reported financial results for the first quarter ended March 31, 2021 and provided a business...
NASDAQ: AZN Long Term Investor Notice: Investigation of Potential Wrongdoing at AstraZeneca PLC
May 10, 2021
San Diego, CA -- (SBWIRE) -- 05/10/2021 -- An investigation on behalf of current long term investors in AstraZeneca PLC (NASDAQ: AZN) shares over possible breaches of fiduciary duty by certain officers...
IMFINZI and tremelimumab With Chemotherapy Demonstrated Overall Survival Benefit in POSEIDON Trial for 1st-line Stage IV Non-small Cell Lung Cancer
May 07, 2021
POSEIDON was a Phase III trial of AstraZeneca’s IMFINZI® (durvalumab) plus platinum-based chemotherapy or IMFINZI, tremelimumab and chemotherapy versus chemotherapy alone in the 1st-line treatment of...
A New Technology that Could Reshape the Vaccine Playing Field (NASDAQ: DYAI) (NASDAQ: AZN) (NASDAQ: MRNA) (NASDAQ: NVAX) (NYSE: PFE) (NYSE: JNJ) (NASDAQ: BNTX)
May 06, 2021
Alchemab to Collaborate With AstraZeneca to Use Alchemab’s Drug Discovery Platform for Prostate Cancer Study
May 05, 2021
Alchemab, a biotech company developing novel therapeutics for patients with hard-to-treat diseases by harnessing the power of naturally protective antibodies, has formed a collaboration with...
Biotechs Zero in on Growing Ovarian Cancer Market as Pivotal Trials Advance Through Regulatory Agencies
May 03, 2021
FARXIGA Approved in the US for the Treatment of Chronic Kidney Disease in Patients at Risk of Progression With and Without Type 2 Diabetes
April 30, 2021
AstraZeneca’s FARXIGA® (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the US to reduce the risk of sustained estimated glomerular filtration rate (eGFR)...